title: [Radioactive seed 125I implantation in treating recurrence and metastasis after liver transplantation in hepatoma].
abstract: OBJECTIVE
  To investigate the clinical value of CT-guided radioactive seed (125)I implantation in treating recurrence and metastasis after liver transplantation in hepatoma.
  
  
  METHODS
  Eleven patients with recurrence and metastasis after liver transplantation for hepatoma, with 45 metastatic lesions, 2.5 cm in diameter on average totally 9 males and 2 females, aged 56 (35 approximately 68), underwent CT-guided radioactive seed 125I implantation for 33 man-times. 125I seeds of the radioactivity of 30 MBq at a distance of 0.5 approximately 1.0 cm were implanted into the recurrence and metastasis lesions according to TPS system before the operation. The matched peripheral dosage (MPD) was 100 approximately 150 Gy, and the number of radioactive seeds for one patient ranged 10 approximately 100.
  
  
  RESULTS
  Among the 45 lesions, 17 obtained CR, 20 PR, 7 NC, and 1 PD. The response rate was 82.2%. Side effects occurred during the procedure including pneumothorax in 1 cases with the lung compressed less than 30 percent, bleeding in 3 cases, and blood in sputum and defervescence in 5 cases. Seeds migration 2 months after the operation occurred in 2 cases. WBC decreased slightly in 2 cases 2 weeks after the operation, with the WBC count >or= 3 x 10(9)/L. No other severe complications, such as massive hemorrhage, bile fistulae, and pancreatic fistula were seen.
  
  
  CONCLUSIONS
  CT guided radioactive seed 125I implantation procedure has good clinical effects with minimal damage and few complications in treating recurrence and metastasis after liver transplantation in hepatoma.
authors.affiliation: Department of Imaging and Interventional Radiology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China.
authors.forename: Fu-jun
authors.initials: FJ
authors.lastname: Zhang
authors.forename: Chuan-xing
authors.initials: CX
authors.lastname: Li
authors.forename: Pei-hong
authors.initials: PH
authors.lastname: Wu
authors.forename: Kui
authors.initials: K
authors.lastname: Li
authors.forename: Jin-hua
authors.initials: JH
authors.lastname: Huang
authors.forename: Wei-jun
authors.initials: WJ
authors.lastname: Fan
authors.forename: Liang
authors.initials: L
authors.lastname: Zhang
authors.forename: Yang-kui
authors.initials: YK
authors.lastname: Gu
authors.forename: Ming-jian
authors.initials: MJ
authors.lastname: Lu
authors.forename: Yue-xia
authors.initials: YX
authors.lastname: Wu
authors.forename: Jun-jie
authors.initials: JJ
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000532:radiotherapy*; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy*; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes